ProQR Therapeutics (PRQR) Convertible Debt (2020 - 2021)
ProQR Therapeutics recorded quarterly Convertible Debt of $17.2 billion in Q1 2021, up 4.26% quarter-over-quarter from $16.5 billion in Q4 2020.
ProQR Therapeutics' Convertible Debt history runs 2 years deep, the most recent figure standing at $17.2 billion for Q1 2021.
- In Q1 2021, Convertible Debt changed N/A year-over-year to $17.2 billion; the TTM figure through Mar 2021 stood at $17.2 billion (changed N/A YoY), while the FY2020 annual figure was $15.8 billion, changed N/A from the prior year.
- Convertible Debt came in at $17.2 billion for Q1 2021 at ProQR Therapeutics, up from $16.5 billion in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $17.2 billion in Q1 2021 to a low of $16.5 billion in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 17.17 Bn |
| Dec 31, 2020 | 16.47 Bn |